Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses how glucagon-like peptide-1 receptor agonists, used for type 2 diabetes and obesity, may cause skin aging and hair loss, and explores methylene blue as a potential protective treatment.

This review summarizes recent research into the effects of GLP-1 receptor agonists on skin processes, noting potential benefits for wound healing but also potential cosmetic concerns like facial fat loss and decreased collagen, highlighting the need for more clinical studies to clarify their dermatological impact.

This study found that among users of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide were associated with higher incidences of hair loss, particularly androgenetic alopecia and telogen effluvium, with rapid weight loss identified as a potential contributor to telogen effluvium.

GLP-1 RA medications may be linked to hair loss.

This study reports that GLP-1 receptors and proglucagon are expressed in the skin of newborn mice, with GLP-1 potentially playing a role in skin development and hair follicle formation.

This study found that adults with type 2 diabetes or obesity using semaglutide and tirzepatide experienced higher odds of nonscarring alopecia, such as telogen effluvium, compared to those using other GLP-1 receptor agonists, with hair loss potentially linked to physiologic stress from weight loss.

This review examines how GLP-1 receptor agonists might impact metabolic and reproductive outcomes in polycystic ovary syndrome, but it reports no new clinical findings and highlights the need for further research.

This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.

This review suggests that glucagon-like peptide 1 receptor agonists may play a potentially protective role in managing diabetic foot ulcers, particularly by addressing various underlying pathophysiological aspects.

This narrative review discusses the mixed and evolving evidence regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their influence on erectile dysfunction in men with type 2 diabetes and obesity, highlighting potential benefits and concerns yet to be clarified.

Tirzepatide may improve hair loss by reducing insulin resistance.

This review suggests that, among non-hormonal treatments for menstrual irregularities in adolescents with PCOS, metformin is the most effective and cost-efficient option, particularly in overweight adolescent girls.

Metabolic issues may trigger lymphocytic cicatricial alopecia, and treatments targeting these issues could help.

This narrative review suggests that the association between weight-loss medications and telogen effluvium is primarily due to metabolic changes from rapid weight loss, rather than a direct pharmacological effect on hair follicles.

This study reviews advances in targeted therapies for moderate-severe dermatological conditions like plaque psoriasis and atopic dermatitis, reporting on newly approved treatments and highlighting the need for further innovations in managing rare inflammatory skin diseases through emerging laboratory techniques and trials.

This review discusses various risk factors and potential therapeutic interventions for PCOS but reports no new clinical results.

This study, published in the September issue of the Journal, explores challenges and treatments for curly-textured hair, investigating glucagon-like peptide-1 agonists' impact on hair loss and discussing a promising therapy using adipose stem cell-derived exosomes to promote hair growth.

This review discusses current pharmacological and non-pharmacological treatment strategies for PCOS, emphasizing the need for a personalized, multimodal approach due to incomplete understanding of the syndrome's pathogenesis.

This review investigates the relationship between polycystic ovarian syndrome and the development of type 2 diabetes mellitus but reports no new clinical findings.

This article reviews treatment approaches for polycystic ovary syndrome, highlighting lifestyle changes, medications like metformin for insulin resistance, and fertility therapies, acknowledging the complexities and contraindications involved.

In this case study, a patient developed a rash consistent with acute generalized exanthematous pustulosis after increasing the dose of semaglutide, suggesting that the reaction was likely due to the excipient propylene glycol, highlighting the importance of ingredient analysis and multidisciplinary collaboration for patient safety.

This review explores weight loss interventions during gestation, emphasizing incretin-based therapies' potential to enhance reproductive health and address metabolic changes for better maternal and fetal outcomes.

This study reviews current treatments for PCOS and evaluates Tirzepatide as a potential option for its management, suggesting possible benefits for those with obesity and metabolic syndrome but not for those of normal weight.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

This narrative review found that combined oral contraceptives remain the primary treatment for hirsutism and acne in women with PCOS, but highlighted the need for further research to refine therapeutic options given the variable efficacy and emerging treatments like GLP-1 receptor agonists.

This review observed that semaglutide may have therapeutic benefits for skin conditions like psoriasis and hidradenitis suppurativa, but reports of adverse skin reactions exist, indicating the need for further research to understand its safety and efficacy in dermatology.

This study explores the role of antidiabetic medications, particularly metformin, GLP-1 receptor agonists, and DPP-4 inhibitors, in managing PCOS, highlighting their combination with hormonal therapies and lifestyle interventions for a comprehensive treatment approach.

This case report describes significant symptom improvement and hair regrowth in a man with recalcitrant folliculitis decalvans after starting tirzepatide for weight management, suggesting a potential new therapy avenue.